Skip to main content

Table 2 Included outcomes of interest and minimum follow-up cutoffs

From: Dietary intakes of flavan-3-ols and cardiovascular health: a field synopsis using evidence mapping of randomized trials and prospective cohort studies

Cardiovascular disease (CVD) clinical outcomes (≥ 6 months follow-up), including acute coronary syndrome, angina, arteriosclerosis, atherosclerosis, atrial fibrillation, cerebrovascular disorders, coronary artery disease, heart failure, myocardial infarction, peripheral vascular disease, and venous thromboembolism1
Serum lipids (≥ 3 weeks follow-up),including blood pressure (BP), diastolic BP (DBP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), systolic BP (SBP), total cholesterol, triglycerides
Inflammatory markers (≥ 3 weeks follow-up), including high-sensitivity C-reactive protein (hs-CRP), intercellular adhesion molecule 1 (ICAM-1), interleukins, vascular cell adhesion molecule 1 (VCAM-1)
Metabolic parameters (≥ 1 week follow-up), including blood glucose, diabetes, hemoglobin A1C (HbA1C), homeostatic model assessment and insulin resistance (HOMA-IR), insulin resistance, quantitative insulin sensitivity check index (QUICKI)
Evaluation of endothelial function (any study length, including acute studies), using Endo-PAT, flow-mediated dilation (FMD), pulse-amplitude, pulse wave analysis, pulse wave velocity
  1. 1When outcomes were reported at multiple time points, the results reported at baseline and the final follow-up were extracted